Cancer Immunotherapies: An Old Idea Sparks New Studies, Industry Interest
Using the immune system to fight the deadly disease shows promise, executives say, but vaccines may take years to bring to market. Biotech executives and cancer researchers are excited about a resurgence in basic studies and clinical trials involving immunotherapeutic approaches to fighting the disease. They caution, however, that because cancer is so poorly understood, products in the marketplace may still be years away. FIGHTING THE GOOD FIGHT: A technician from Cytel, one of the many immun
Apr 2, 1995
Using the immune system to fight the deadly disease shows promise, executives say, but vaccines may take years to bring to market. |
![]() FIGHTING THE GOOD FIGHT: A technician from Cytel, one of the many immunotherapeutic biotech firms, works on developing a cancer vaccine. |
Dozens of biotech firms are researching and...
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?